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Abstract 
Objectives: Direct-acting antivirals (DAAs) are successful in curing hepatitis C virus (HCV) 
in over 95% of patients treated for 12 weeks. DAAs are expensive, and shortened treatment 
durations, which may have lower cure rates, have been proposed to reduce costs. We 
evaluated the lifetime cost-effectiveness of different shortened treatment durations for 
genotype 1 non-cirrhotic treatment-naïve patients. 
Methods: Assuming a UK National Health Service perspective, we used a probabilistic 
decision tree and Markov model to compare three unstratified shortened treatment durations 
(eight, six, and four weeks) against a standard 12-week treatment duration. Patients failing 
shortened first-line treatment were retreated with a 12-week treatment regimen. Parameter 
inputs were taken from published studies. 
Results: Eight weeks treatment duration had an expected incremental net monetary benefit 
(INMB) of £7,737 (95% CI £3,242 to £11,819) versus standard 12 weeks treatment, per 
1,000 patients. Six weeks treatment had a positive INMB, although some uncertainty was 
observed. The probability that eight and six weeks treatment was most cost-effective was 
56% and 25%, respectively, while four weeks treatment was 17%. Results were generally 
robust to sensitivity analyses, including a threshold analysis that showed eight weeks 
treatment was most cost-effective at all drug prices below £40,000 per 12-week course. 
Conclusions: Shortening treatments licensed for 12 weeks to eight weeks is cost-effective in 
genotype 1 non-cirrhotic treatment-naïve patients. There was considerable uncertainty in the 
estimates for six and four weeks treatment, with some indication that six weeks treatment 




 The cost-effectiveness of direct-acting antiviral treatment for chronic hepatitis C virus 
has been well documented, although the cost of treatment is considerable. Shortened 
treatment durations have been proposed to reduce costs, albeit at the expense of 
potentially curing fewer patients. 
 Shortening treatment duration from 12 to eight weeks using direct-acting antiviral 
therapy is cost-effective for treatment of mild chronic hepatitis C virus in genotype 1 
non-cirrhotic treatment-naïve patients, provided a retreatment strategy is adopted for 
patients that fail first-line treatment.   
 There was considerable uncertainty in the cost-effectiveness estimates for six and four 
weeks shortened treatment, with some indication that six weeks treatment may be 
cost-effective, but that four weeks treatment may not be cost-effective. More robust 








The cost-effectiveness of direct-acting antiviral (DAA) treatment for chronic hepatitis C virus 
(HCV) has been well documented [1-4], and a wide array of DAA therapies have been 
approved for use internationally [5]. The therapies, which are generally administered orally 
over 12 weeks, are successful in over 95% of patients with chronic HCV genotype 1 (GT1) 
[5]. The advent of an effective cure has brought the potential to address HCV globally. The 
World Health Organisation (WHO) recently outlined its commitment towards eliminating 
HCV by 2030 [6]. However, the cost of a standard 12-week treatment course is high, and 
variations in price exist internationally and across DAA regimens. In the UK, the price set by 
manufacturers initially ranged from £30,000 to £60,000 per patient [7-9], whereas in the US, 
a 12-week course of treatment can cost more than $90,000 per patient [10]. Although 
significantly lower prices have been agreed between manufacturers and health care payers, 
these prices have not been made publicly available. Shortened treatment duration is one 
mechanism that could be used to reduce drug costs, albeit at the expense of potentially curing 
fewer patients.  
Recent evidence suggests shortened treatment durations are associated with lower cure rates 
in GT1 non-cirrhotic treatment-naïve patients. Kowdley et al. [11] reported that the cure rate 
fell from 96% in patients treated for 12 weeks using a triple DAA regimen (ombitasvir-
paritaprevir-ritonavir with dasabuvir (3D)) to 88% in patients treated for eight weeks with the 
same regimen. Sulkowski et al. [12] considered shorter treatment durations using a 
combination of four DAAs (daclatasvir, asunaprevir, beclabuvir, and sofosbuvir (DCV-Trio + 
SOF)) and found 57% and 29% of patients treated over six and four weeks, respectively, 
cleared the virus. Other studies considered the effectiveness of existing DAA therapies over 
shortened treatment durations, but with the addition of an investigational non-nucleoside or 
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protease inhibitor. For example, Kohli et al. [13] found 40% of patients were cured when 
treated for four weeks using ledipasvir and sofosbuvir (LDV/SOF) plus a non-nucleoside 
inhibitor (GS9669).  
Although cure rates are lower over shortened treatment durations, patients can usually be 
retreated with an alternative, or similar, DAA regimen if first-line treatment fails. One 
concern with first-line treatment failure, however, is patients can develop resistance to DAA 
therapies and this can affect the likelihood of future viral eradication [14]. However, much 
evidence suggests non-cirrhotic patients with DAA resistance, or resistance-associated 
polymorphisms, can clear the virus with further treatment [15-19] even before the advent of 
combinations with broader antiviral activity. Wilson et al. [19] found 90% of patients with 
DAA resistance were cured with 12 weeks retreatment using LDV/SOF, while 91% of 
patients overall were cured, following shortened first-line treatment failure. Bourliere et al. 
[20] found 97% of patients that previously failed first-line treatment cleared the virus over 12 
weeks using sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX).  
Given the burden of high treatment costs, and the potential to cure as many patients using 
shortened treatment durations (with a retreatment strategy adopted for all patients that fail 
first-line treatment), the cost-effectiveness of short-course therapy needs to be considered. In 
this paper, we compared the lifetime cost-effectiveness of different unstratified shortened 
treatment durations. We modelled outcomes for GT1 non-cirrhotic treatment-naïve patients 
with HCV in the UK, for whom shortened treatment has been reported in the literature, and 
for whom shortened treatment may be considered in the future.  
Methods 
We used a decision tree and Markov model to investigate the cost-effectiveness of shortened 
DAA treatment from the National Health Service (NHS) perspective in the UK. We applied 
5 
 
monthly cycles during the first year in the decision tree to simulate treatment outcomes and 
annual cycles in the Markov model to simulate the natural history of HCV. We adopted a 
lifetime time horizon (60 years, from an initial age of 40) and discounted costs and utilities at 
3.5% per annum, as per NICE guidelines [21].  
Target population 
The model simulated outcomes for GT1 non-cirrhotic treatment-naïve patients infected with 
HCV, combining data from sub-types 1a and1b. We modelled outcomes for a representative 
population with non-cirrhotic HCV in the UK, based on Hartwell et al. [22]. At baseline, 
51.1% and 48.9% of patients had mild (F0-F1) and moderate (F2-F3) liver fibrosis, 
respectively. At model entry, patients were aged 40 years and 70% were male (Table 1).  
Treatment comparators and regimens 
We compared three unstratified shortened treatment durations (eight, six, and four weeks) 
against the standard 12-week treatment duration. We considered treatment regimens currently 
used in the UK in our analysis. In the base case analysis, we used a triple-DAA regimen (3D) 
for first-line treatment due to the availability of data on the effectiveness of shortened 
treatment [11]. 3D contains two fixed-dose tablets with 12.5mg ombitasvir, 75mg 
paritaprevir, and 50mg ritonavir, which are taken daily along with one-dose 250mg dasabuvir 
[8].  
We assumed patients that failed first-line treatment were retreated for 12 weeks, as per recent 
UK guidelines [23, 24]. We used SOF/VEL/VOX as the salvage regimen. SOF/VEL/VOX is 
a non-structural protein 5A (NS5A) inhibitor-containing regimen that is administered once 
daily using a fixed-dose tablet; each tablet contains 400mg sofosbuvir, 100mg velpatasvir 
(NS5A inhibitor) and 100mg voxilaprevir (protease inhibitor) [25]. SOF/VEL/VOX is the 
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currently recommended treatment regimen for patients that previously failed first-line 
treatment in the UK [23, 24]. 
Model structure 
The decision tree was designed to capture treatment outcomes in the first year using monthly 
cycles (Figure 1a). Patients were assessed for sustained virological response at 12 weeks post 
treatment (SVR12, effective cure), which was defined as having HCV ribonucleic acid 
(RNA) less than 25 IU per millilitre. Patients that failed first-line treatment were retreated at 
24 weeks. All patients entered the Markov model based on their response to treatment.  
The Markov model was adapted from previously validated models that characterise the 
natural disease history of HCV [3, 22, 26, 27]. Patients entered the model based on their 
initial distribution of liver fibrosis (mild or moderate), and whether treatment had been 
successful (Figure 1b). In HCV-cleared patients, we modelled potential reinfection. Patients 
without SVR12 could progress from mild (F0-F1) to moderate (F2-F3) to severe liver 
fibrosis, or compensated cirrhosis (F4). Once in this health state, patients could develop more 
advanced liver disease, including hepatocellular carcinoma and decompensated cirrhosis. 
Patients with decompensated cirrhosis were also at risk of hepatocellular carcinoma, with 
both groups of patients at risk of requiring a liver transplant. We modelled liver-related 
deaths for each of these advanced health states with two health states captured in the 
hepatocellular carcinoma and liver transplant health states to reflect the initial and subsequent 
risk of liver-related mortality. At any stage in the Markov model, patients could die from 




We assumed there was no progression to more severe health states during treatment, such as 
compensated cirrhosis (F4), or once treatment had been successful. Only if patients became 
re-infected could disease progression occur. There are no clinical guidelines on the 
appropriate length of time patients should wait before a salvage treatment is administered. In 
our model, we assumed the wait time did not affect the success of retreatment.    
Parameter inputs 
We informed the model using a synthesis of evidence, as summarised in Table 1 and 
described below.  
Treatment-related inputs 
We synthesised evidence from two sources to inform the efficacy of first-line 3D treatment. 
Kowdley et al. [11] reported SVR12 for 3D following 12 and eight weeks treatment, based on 
a large phase 2b clinical trial with 571 patients, and found 96% and 88% of patients, 
respectively, cleared the virus. Evidence on shorter treatment durations for 3D were not 
available, however, SVR12 for an alternative DAA regimen using DCV-Trio + SOF was 
reported by Sulkowski et al. [12] for a similar population following six and four weeks 
treatment. The small phase 2 clinical trial with 28 patients reported that 57% and 29% of 
patients achieved SVR12 following six and four weeks treatment, respectively. For our 
analysis, we assumed the odds ratio of SVR12 following six and four weeks treatment using 
DCV-Trio + SOF could be applied to 3D. We calculated the odds ratio of available data (i.e., 
eight versus 12 weeks and four versus six weeks), averaged these to estimate eight versus six 
weeks, and applied these to our baseline 3D estimates to obtain predicted estimates for six 
and four weeks for 3D therapy. We used a Bayesian Markov chain Monte Carlo (MCMC) 
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simulation framework to pool the evidence to propagate and reflect the uncertainties in these 
estimates for use in probabilistic sensitivity analysis (see Appendix 1 for further details). The 
estimated SVR12 was 96%, 87%, 64%, and 38% following 12, eight, six, and four weeks 
treatment, respectively, with uncertainty around these estimates given in Table 1.  
Bourliere et al. [20] provided evidence on the efficacy of retreatment using SOF/VEL/VOX 
from two phase 3 clinical trials (POLARIS-1 and POLARIS-4). Overall, 97.3% of patients 
achieved SVR12; we used this parameter to inform the expected SVR12 in patients that failed 
any of the treatment strategies. We assessed uncertainty in this parameter using data obtained 
from Bourliere et al. [20] and beta distributions. 
Treatment-related adverse events associated with DAA treatment were modelled to reflect the 
potential impact of these clinical events over different treatment durations. We obtained the 
probability of adverse events occurring from a clinical trial of 3D treatment, as reported by 
Johnson et al. [3]. To estimate the probability of these events occurring over different 
treatment durations, we converted the probabilities to rates and calculated the time-dependent 
probability for each strategy (Appendix 2). We assumed the probability of adverse events 
occurring was the same for retreatment as for first-line treatment. The adverse events 
included anemia, rash, depression, grade 3 or 4 neutropenia, and grades 3 or 4 
thrombocytopenia.  
Epidemiological inputs 
The Markov model simulated the natural disease history of HCV using annual transition 
probabilities, which are presented in Table 1. We derived estimates from published studies on 
the probability of reinfection (1% per annum) [3], fibrosis [28, 29] and non-fibrosis [30, 31] 
progression, liver-related mortality [28, 31, 32], and all-cause mortality, stratified by age and 





The model considered both treatment-related and health state costs from the perspective of 
the NHS in the UK (Table 1). All unit costs were expressed in Sterling (£) and valued at 
2016/17 prices. 
The costs for the drug regimens were taken from the respective NICE technology appraisals 
for 3D [8] and SOF/VEL/VOX [25] (Table 1). These costs were applied on a pay-per-tablet 
basis, rather than pay-per-treatment success basis. We also considered monitoring costs, and 
derived these from a previous technology appraisal for a similar DAA [7]. We assumed 
monitoring costs were the same for first-line treatment and retreatment, as these costs were 
not expected to vary by DAA treatment. Treatment-related costs (drug and monitoring costs) 
were assumed to be fixed in the model as these prices were not expected to vary in the UK. 
The costs associated with adverse events were taken from Johnson et al. [3]. We assessed 
uncertainty in these estimates using gamma distributions. 
Health state costs were derived from a previous UK evaluation of HCV by Hartwell et al. 
[22] and a cost analysis of resource use incurred by both HCV-infected and -cleared patients, 
undertaken by Backx et al. [34]. Gamma distributions were assumed for all cost inputs. We 
updated costs to 2016/17 prices using the Hospital and Community Health Services (HCHS) 
index [35] (Table 1). 
Utility weights 
We derived treatment-related and health state utility estimates from published studies (Table 
1). Johnson et al. [3] provided treatment-related utilities for 3D treatment. The quality of life 
estimates were obtained from the EQ-5D-5L questionnaire, which was administered to 
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patients participating in clinical trials for 3D treatment. For our analysis of shortened 
treatment, we converted the 12-week treatment estimates to reflect the monthly deterioration 
in quality of life due to adverse events associated with treatment. We assumed the same 
treatment-related utilities for SOF/VEL/VOX as these have not yet been published.    
Health state utilities for HCV infection were derived from Wright et al. [29], and reflected the 
expected annual health-related quality of life associated with each HCV health state. As in 
Wright et al. [29], and other analyses [3, 22], we assumed the health utility associated with 
treatment success (SVR12) was greater than the baseline utility level by a score of 0.05 for 
both mild and moderate liver fibrosis. We assumed the health utility in successfully treated 
patients was fixed in the model. We investigated uncertainty in infected patients using beta 
distributions (Table 1).  
Cost-effectiveness analyses  
Base case analysis 
The base case analysis compared the lifetime cost-effectiveness of different shortened 
treatment durations against the standard 12-week treatment duration for GT1 non-cirrhotic 
treatment-naïve patients in the UK. We calculated expected costs and quality-adjusted life 
years (QALYs) per 1,000 patients using a probabilistic analysis, with parameters sampled 
from predefined distributions over 10,000 simulations in Microsoft Excel software [36]. The 
expected costs and QALYs were computed as an average over the 10,000 simulations. We 
calculated the expected incremental net monetary benefit (INMB) of each shortened 
treatment strategy relative to 12 weeks treatment, assuming £20,000 willingness-to-pay 
(WTP): 
Expected INMB = (𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑄𝐴𝐿𝑌𝑠) ∗ £20,000 − (𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑐𝑜𝑠𝑡𝑠) 
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 We also calculated the expected cost per cure:  




where pCured is the proportion of patients cured over the treatment duration. We reported the 
probability that any strategy was the most cost-effective treatment strategy at different WTP 
thresholds using cost-effectiveness acceptability curves.  
Sensitivity analyses 
We considered alternative DAA regimens currently used in the UK as first-line treatment to 
assess the impact of different drug prices and utility scores on cost-effectiveness. These 
included LDV/SOF, daclatasvir plus sofosbuvir (DCV/SOF), and elbasvir/grazoprevir 
(ELB/GZR). (The cost and utility estimates used in these analyses are detailed in Appendix 
3.)  
We assessed the impact on cost-effectiveness of lower drug prices. The base case analysis 
used prices reported in the NICE technology appraisals, however, reduced drug prices were 
agreed by the drug manufacturers and NICE, which have not been made publicly available. In 
a sensitivity analysis, we reduced drug prices by 80% (to £7,284.34 and £8,965.40 per 12-
week course for first-line treatment and retreatment, respectively). We considered alternative 
discount rates in sensitivity analyses to assess the impact of lower (1.5%) and higher (5%) 
discount rates on cost-effectiveness findings. This was useful to assess the generalisability of 
our findings to other health care settings where different discount rates are applied. Here, we 




Due to uncertainty in the cost of treatment in the UK and elsewhere, we used a threshold 
analysis to investigate cost-effectiveness under different drug prices. Here, we ranged the cost 
from zero to £40,000 per 12-week course for both first-line treatment and retreatment 
simultaneously.  
We also used threshold analyses to investigate the impact of different first-line cure rates on 
cost-effectiveness for each shortened treatment strategy separately, assuming the same 80% 
reduction in drug prices. First, we considered higher SVR rates for eight weeks treatment, 
holding all else constant, as the base case rate of 87% was somewhat conservative; higher 
success rates over eight weeks have been reported for other regimens [37], as well as newer 
DAAs [38]. In this scenario, we ranged SVR12 between 86% and 96%. Following six weeks 
treatment, we varied the first-line cure rate between 40% and 85% (i.e., between the SVR12 
following four (38%) and eight (87%) weeks treatment), holding all else constant. Lastly, we 
investigated the cost-effectiveness of four weeks treatment at higher cure rate thresholds, 
constrained at 65% (i.e., constrained at the SVR12 following six weeks treatment).  
Due to some uncertainty in the cure rate following retreatment, we conducted a threshold 
analysis on this parameter also. Here, we varied the cure rate between zero and 100% and 
assumed the same thresholds for each shortened treatment strategy. We assumed the same 
80% reduction in drug prices in this scenario also.  
Results 
Base case findings 
Eight weeks treatment generated lower expected lifetime costs and fewer QALY gains 
compared with 12 weeks treatment. The strategy had the lowest expected lifetime cost per 
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cure at £32,607 (95% CI £29,288 to £36,699). At £20,000 WTP, despite the smaller QALY 
gains, the strategy had the highest INMB per 1,000 patients at £7,737 (95% CI £3,242 to 
£11,819) due to the considerable cost savings associated with the shortened treatment 
strategy (Table 2). At 56%, the strategy had the highest probability of being the most cost-
effective option. Six weeks treatment produced a positive expected INMB, although some 
uncertainty was observed due to imprecise estimates on the effectiveness of shortened 
treatment (INMB £1,860 (95% CI £-14,517 to £15,153)). The strategy had a lower 
probability of being most cost-effective at 25%. Similar uncertainty was observed in the four-
week treatment strategy, which produced a negative expected INMB (£-4,735 (95% CI £-
24,197 to £20,141)) due to higher overall lifetime costs and lower QALY gains. The strategy 
had 17% probability of being most cost-effective.  
Sensitivity analyses findings 
Changing the drug regimen for first-line treatment did not affect the base case findings, 
except in the case of the four-week treatment strategy which produced a positive INMB using 
DCV/SOF as first-line treatment. The main driver for this change was the increased cost of 
first-line treatment, which increased the overall cost of 12 weeks treatment. In all cases, the 
eight- and six-week treatment strategies produced a positive expected INMB (Appendix 3). 
Greater uncertainty was observed when DCV/SOF was used as first-line treatment, however, 
the shortened treatment strategies had comparably higher probabilities of being the most cost-
effective treatment strategies compared to 12 weeks treatment (Appendix 3). 
Reducing drug costs by 80% introduced some uncertainty in the results. Due to the reduced 
cost-saving, the eight weeks treatment strategy returned a considerably smaller INMB with 
some uncertainty observed (£1,370 (95% CI £-344 to£2,685)). However, the strategy still had 
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the highest probability (47%) of being most cost-effective due to lower expected lifetime 
costs (Table 2; CEAC presented in Appendix 4).  
The results were robust to changes in the discount rate (Appendix 5). At the lower rate of 
1.5%, the same uncertainty was observed, and the eight-week strategy still had the highest 
probability of being most cost-effective, at 46%. At the higher rate of 5.0%, the probability 
that eight weeks treatment was most cost-effective increased to 50% and no uncertainty in the 
expected INMB was observed.   
Scenario analyses findings 
Figure 2 presents the findings from the drug-cost threshold analysis. The results are plotted 
using information on the probability of cost-effectiveness at £20,000 WTP. The horizontal 
axis presents the different drug costs. At zero drug costs, 12 weeks treatment was the most 
cost-effective option due to the obvious QALY advantage over the shortened treatment 
strategies. However, eight weeks treatment had the highest probability of being most cost-
effective at all drug costs above zero due to the available cost-savings. At all prices above 
£6,000 per 12-week course, six weeks treatment had a consistently higher probability (>20%) 
than 12 weeks treatment of being most cost-effective.  Four weeks treatment had consistently 
low (<20%) probability of being the most cost-effective strategy at all drug prices.  
Figure 3 presents the findings from the first-line cure rate threshold analysis following eight, 
six, and four weeks treatment, respectively. The results are similarly plotted using 
information on the probability of cost-effectiveness. The probability that eight weeks 
treatment duration is cost-effective increases with each percentage increase in SVR12 (Figure 
3a). At 96% SVR12, ceteris paribus, the probability that the strategy is most cost-effective is 
60%. If SVR12 following six weeks treatment was 77% or higher, ceteris paribus, the 
strategy had the highest probability of being the most cost-effective strategy (Figure 3b). Four 
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weeks treatment had lowest probability of being most cost-effective, even when SVR12 was 
as high as 65% (Figure 3c).  
The results from the retreatment cure rate threshold analysis are presented in Figure 4. At 
retreatment cure rates above 65%, eight weeks treatment had the highest probability of being 
the most cost-effective strategy. Six and four weeks treatment had a higher probability of 
being cost-effective compared with 12 weeks treatment if SVR12 following retreatment was 
92.5% and 97.5% or higher, respectively.  
Conclusions 
We compared the lifetime cost-effectiveness of three unstratified shortened treatment 
durations (eight, six, and four weeks) against 12 weeks treatment, with a retreatment strategy 
adopted for all patients that failed first-line treatment, for GT1 non-cirrhotic treatment-naïve 
patients in the UK. Eight weeks treatment generates marginally fewer expected lifetime 
QALYs than standard 12 weeks treatment duration, but is the most cost-effective option due 
to considerably lower expected lifetime costs arising from lower first-line treatment costs. 
There is considerable uncertainty surrounding the cost-effectiveness of six and four weeks 
treatment due to limited evidence on efficacy, although there is some indication that six 
weeks treatment may be cost-effective, while four weeks treatment is likely not cost-
effective.  
Provided drug costs are above zero, eight weeks treatment has the highest probability of 
being most cost-effective due to the available cost-savings versus standard 12 weeks 
treatment duration. Six weeks treatment had a higher probability than 12 weeks treatment of 
being most cost-effective at all drug prices above £6,000 per 12-week course, however, the 
probability was generally low at ~30%. Eight weeks treatment is highly cost-effective at 
higher first-line cure rates; at 96% SVR12, the strategy has 60% probability of being most 
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cost-effective. Six weeks treatment would be the most cost-effective option if the first-line 
cure rate was 77% or higher, while four weeks treatment always had a low probability of 
being most cost-effective, even when the first-line cure rate was as high as 65%. Shortening 
treatment duration is cost-effective if the retreatment cure rate is 65% or higher following 
eight weeks treatment, or 92.5% and 97.5% following six and four weeks treatment, 
respectively.  
Discussion 
Strengths and limitations 
This is the first study to consider the cost-effectiveness of short-course therapy for chronic 
HCV, to the best of our knowledge. We compared three different shortened treatment 
durations using data reported in the literature for a non-cirrhotic treatment-naïve population. 
We developed a decision tree to capture treatment outcomes and adapted a previously 
validated Markov model to reflect the disease history of HCV. We assessed a number of 
DAA regimens currently used in the UK and conducted a variety of sensitivity and scenario 
analyses. Our results were generally robust to these analyses.  
There are limitations to this work. The evidence on the effectiveness of shortened treatment 
duration is limited, and often limited to DAAs not currently approved. With the exception of 
Kowdley et al. [11] who reported the effectiveness of 3D treatment, which is currently 
recommended for use internationally, the majority of studies considered the effectiveness of a 
combination of DAA regimens [12], or explored the effectiveness of existing DAA regimens 
but with the addition of an investigational non-nucleoside or protease inhibitor, for example 
[13, 39, 40]. As a consequence, these analyses have had little impact on policy. For instance, 
in the UK, the recommended standard treatment duration for all DAA regimens in GT1 is 12-
16 weeks, with the exception of LDV/SOF which is recommended for use over eight weeks 
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in patients with low baseline viral load, and glecaprevir/pibrentasvir which is a new regimen 
that is licensed for use over eight weeks[41]. Although the evidence is limited, we used 
Kowdley et al. [11] as our baseline source for efficacy data on 12 and eight weeks treatment 
and predicted the expected cure rate for this regimen over six and four weeks duration using 
data from Sulkowski et al. [12].  
The evidence for the effectiveness of retreatment is also limited, although the majority of 
studies report considerably high success rates in GT1 non-cirrhotic patients [15, 17-20, 42]. 
For our analysis, we used recent evidence from Bourliere et al. [20] who investigated the 
effectiveness of retreatment using the now currently recommended retreatment regimen 
(SOF/VEL/VOX) over 12 weeks for a similar non-cirrhotic population that fail first-line 
therapy. In scenario analysis, we assessed lower retreatment cure rates and found the 
shortened treatment strategies were more cost-effective than 12 weeks treatment provided 
SVR12 following retreatment was 65% or higher following eight weeks treatment, and 92.5% 
and 97.5% following six and four weeks treatment, respectively.  
Although the cost of DAA treatment is high, we do not know the actual price health care 
payers pay for these drugs. In our base case analysis, we assumed the prices reported in the 
technology appraisals [7-9, 43], which are an exaggeration of the actual prices paid. In a 
threshold analysis, we varied these prices and found the base case findings remained 
generally robust at prices below £40,000 per 12-week course.  
Finally, we took a UK perspective in this paper. Although some variations in monitoring 
costs might exist internationally, there is little to differentiate in terms of treatment costs, 
patient outcomes, and disease progression. Discount rates differ across some settings; for 
instance, in Australia, Estonia, Latvia, Lithuania, and Ireland, the applied discount rate is 5%, 
while in Canada it is 1.5% [44]. We applied these rates in sensitivity analyses and found the 
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results remained generally unchanged, suggesting our findings may be generalisable to other 
health care settings that assume the same, or either lower or higher discount rates. The 
findings are also likely generalisable across DAA regimens, which are generally 
homogenous; DAAs have similar cure rates, comparably high treatment costs, and impact 
patient’s quality of life uniformly. We did not explore strategies that might stratify patients as 
suitable for shortened therapy at four and six weeks, though such approaches are likely to 
improve the cost-effectiveness of treatment.  
Implications for practice 
Our findings that eight or even six) weeks shortened treatment duration is likely to be cost-
effective are important in the context of clinical practice. Treating patients over shortened 
durations in resource-constrained settings, for example, allows scarce resources, such as staff, 
to be better allocated and distributed although such approaches need to be balanced against 
the complexity of delivering care. The decision to treat patients, particularly those with high 
loss to follow up, such as chaotic drug users, is also less problematic. Treating these patients 
over shortened treatment durations is effective and cost-effective if a salvage treatment can 
be administered. This may be useful in settings where there is a limited time available for 
treatment, e.g. prisons; however, the decision to treat patients serving short sentences remains 
problematic due to loss to follow up. Future research should identify the potential cost-
effectiveness of shortened treatment durations in this context.  
Although short-course therapy is not currently recommended, the cost-effectiveness of this 
approach is clear. Shortening treatment to eight or six weeks using existing DAA therapies, 
such as 3D, LDV/SOF, DCV/SOF, and ELB/GZR appears cost-effective, although some 
uncertainty in the six-week treatment strategy exists. We highlight the need for further 
evidence on the efficacy of six and four weeks treatment using licensed regimens, along with 
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evidence on the success of retreatment. Future research should also identify patients for 
whom shortened treatment is likely to be effective, with treatment duration optimised based 
on baseline viral load or resistance to DAA therapies, for example, which has been shown to 
limit patients chance of viral eradication [45, 46], particularly in those with prolonged 
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Table 1 Summary of treatment, epidemiological, cost, and quality of life inputs for probabilistic sensitivity 
analyses 
Variable Base case Distributio
n 
Alpha Beta Source 
Patient characteristics      
Initial distribution of liver fibrosis      
    Mild (F0-F1) 51.1% - - - [22] 
    Moderate (F2-F3) 48.9% - - - [22] 
Age 40 - - - [22] 
Male 70% - - - [22] 
Efficacy (SVR12)      
First-line treatment          
    12 weeks 0.96 Beta 76 3 [11] 
    8 weeks 0.87 Beta 69 10 [11] 
    6 weeks 0.64 Beta 6 3 [12]
a
 
    4 weeks 0.38 Beta 1 2 [12]
a
 
Retreatment           
    12 weeks 0.91 Beta 31 3 [19] 
Annual transition probabilities           
Fibrosis progression           
    Mild-to-moderate 0.025 Beta 38 1484 [28, 29] 
    Moderate-to-CC 0.037 Beta 27 699 [28, 29] 
Non-fibrosis progression           
    CC-to-DCC 0.039 Beta 15 359 [31] 
    CC-to-HCC 0.014 Beta 2 135 [30] 
    DCC-to-HCC 0.014 Beta 2 135 [30] 
    HCC-to-liver transplant 0.020 Beta 98 4801 [22] 
    DCC-to-liver transplant 0.020 Beta 98 4801 [28] 
Liver-related mortality           
    DCC-to-liver death 0.130 Beta 147 983 [31] 
    HCC-to-liver death (first year) 0.430 Beta 117 155 [31] 
    HCC-to-liver death (subsequent year) 0.430 Beta 117 155 [31] 
    Liver transplant-to-liver death (first year) 0.150 Beta 85 481 [28] 
    Liver transplant-to-liver death (subsequent 
year) 
0.057 Beta 85 1407 [32] 
Reinfection 0.010 Beta 4 391 [3] 
Costs           
Treatment-related costs           
    3D (monthly) £12,140.56 Fixed - - [8] 
    SOF/VEL/VOX (monthly) £14,942.33 Fixed - - [25] 
    Monitoring costs (monthly) £162.34 Fixed - - [7] 
Health state costs           
    SVR Mild (F0-F1) £60.36 Gamma 34 2 [34] 
    SVR moderate (F2-F3) £60.36 Gamma 34 2 [34] 
    Mild (F0-F1) £166.50 Gamma 13 13 [22] 
    Moderate (F2-F3) £612.50 Gamma 35 17 [34] 
    CC (F4) £951.13 Gamma 17 54 [34] 
    DCC £12,833.96 Gamma 15 849 [22] 
    HCC (first year) £11,436.41 Gamma 13 894 [22] 
    HCC (subsequent year) £11,436.41 Gamma 13 894 [22] 
    Liver transplant (first year) £51,769.79 Gamma 15 3473 [22] 
    Liver transplant (subsequent year) £1,949.08 Gamma 14 136 [22] 
Adverse event costs      
    Anemia £501.58 Gamma 10 48 [3] 
    Rash £166.50 Gamma 16 10 [3] 
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    Depression £414.17 Gamma 16 26 [3] 
    Neutropenia £980.26 Gamma 10 98 [3] 
    Thrombocytopenia £875.16 Gamma 14 62 [3] 
Utilities           
Treatment-related utilities (penalties)            
    Mild (F0-F1) - 3D (monthly) -0.001 Fixed - - [3] 
    Moderate (F2-F3) - 3D (monthly) -0.001 Fixed - - [3] 
Health state utilities           
    SVR mild (F0-F1) 0.820 Fixed - - [29] 
    SVR moderate (F2-F3) 0.710 Fixed - - [29] 
    Mild (F0-F1) 0.770 Beta 141 42 [29] 
    Moderate (F2-F3) 0.660 Log-
normal 
- - [29] 
    CC (F4) 0.550 Log-
normal 
- - [29] 
    DCC 0.450 Beta 55 67 [29] 
    HCC (first year) 0.450 Beta 55 67 [29] 
    HCC (subsequent year) 0.450 Beta 55 67 [29] 
    Liver transplant (first year) 0.450 Beta 55 67 [22] 
    Liver transplant (subsequent year) 0.670 Beta 32 16 [29] 
a
 Synthesised from Kowdley et al. [11] and Sulkowski et al. [12]: see Appendix 1 for further details. 
SVR12, sustained virological response at 12 weeks; CC, compensated cirrhosis; DCC, decompensated cirrhosis; 
HCC, hepatocellular carcinoma; 3D, ombitasvir, paritaprevir ritonavir with dasabuvir; SOF/VEL/VOX; 




Table 2 Cost-effectiveness findings 













Base case analysis 
12 weeks £40,911  
(£38,742 to £44,007) 
15.51  
(15.00 to 16.16) 
£41,051  
(£38,788 to £44,313) 
- 0.029 
8 weeks £32,821  
(£29,513 to £36,971) 
15.49  
(14.98 to 16.14) 
£33,194  
(£29,701 to £37,669) 
£7,737  
(£3,242 to £11,819) 
0.558 
6 weeks £37,668  
(£25,511 to £52,476) 
15.44  
(14.92 to 16.11) 
£39,048  
(£25,746 to £56,050) 
£1,860  
(£-14,517 to £15,153) 
0.245 
4 weeks £43,126  
(£20,506 to £59,551) 
15.38  
(14.83 to 16.07) 
£46,021  
(£20,762 to £67,835) 
£-4,735  
(£-24,197 to £20,141) 
0.168 
Sensitivity analysis (80% reduction in drug prices) 
12 weeks £11,455 
 (£9,951 to £13,657) 
15.51  
(14.99 to 16.16) 
£11,495  
(£9,972 to £13,721) 
- 0.220 
8 weeks £9,738  
(£8,083 to £12,016) 
15.49  
(14.97 to 16.14) 
£9,848  
(£8,136 to £12,217) 
£1,370  
(£-344 to £2,685) 
0.470 
6 weeks £10,892  
(£7,617 to £14,835) 
15.44  
(14.9 to 16.11) 
£11290  
(£7,709 to £15,949) 
£-815  
(£-6,868 to £3,170) 
0.203 
4 weeks £12,203  
(£6,634 to £17,020) 
15.38  
(14.82 to 16.07) 
£13,008  
(£6,706 to £19,512) 
£-3,197  
(£-12,090 to £4,291) 
0.107 
a
 Versus 12 weeks 
b
 At £20,000 willingness-to-pay         
QALYs, quality-adjusted life years; INMB, incremental net monetary benefit; p(CE), probability most cost-







Figure 1 Economic model structure 
(a) Decision tree simulating treatment outcomes 
(b) Markov model simulating natural disease history 
Figure 2 Probability of cost-effectiveness at £20,000 willingness-to-pay and different drug 
costs 
Figure 3 Probability of cost-effectiveness at £20,000 willingness-to-pay and different first-
line cure rate thresholds  
(a) Eight weeks treatment 
(b) Six weeks treatment 
(c) Four weeks treatment  
Figure 4 Probability of cost-effectiveness at £20,000 willingness-to-pay and different 
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